natgillin/translations-raw huggingface dataset:
Tell your oncologist and dentist immediately if you experience such symptoms.
- reakcije prebavil, na primer slabost s siljenjem na bruhanje (navzeja) in bruhanje, pa tudi izguba
Other common side effects are: − Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite. − Conjunctivitis, as reported with other bisphosphonates (the group of substances to which Zometa belongs). − Blood tests indicating changes in kidney function (higher levels of creatinine), including severe kidney impairment; such changes are also known to occur with other medicinal products of this kind.
- konjunktivitis (vnetje očesne veznice), o katerem poročajo pri drugih difosfonatih (skupina
In addition, some cases of kidney disease have been reported.
Poleg tega so poročali o nekaj primerih bolezni ledvic.
Occasional side effects may also include hypersensitivity reactions, high blood pressure, shortness of breath, dizziness, sleep disturbances, tingling or numbness of the hands or feet or diarrhoea.
Občasni neželeni učinki lahko obsegajo tudi preobčutljivostne reakcije, zvišan krvni tlak, kratko sapo, vrtoglavost, motnje spanja, mravljinčenje ali odrevenelost dlani ali stopal, ali drisko.
Cases of low blood pressure have also occasionally been reported; in very rare cases, this resulted in fainting.
Občasno so poročali tudi o primerih nizkega krvnega tlaka, zaradi katerega je zelo redko prišlo do izgube zavesti.
Uncommonly, skin reactions (redness and swelling) at the infusion site may occur and cases of rash, itching and chest pain have been observed.
Redkeje se lahko na mestu infuzije pojavijo kožne reakcije (rdečina in otekanje), opazili so tudi primere izpuščaja, srbenja in bolečin v prsih.
Rarely, slow heart beat and confusion occurred.
Redko sta se pojavila upočasnjen srčni utrip in zmedenost.
Anaemia, a condition in which the number of red blood cells is decreased, has been reported; low counts of white blood cells and blood platelets have been observed in some cases.
Poročajo o anemiji, pri kateri je zmanjšano število rdečih krvničk; v nekaterih primerih so opazili zmanjšano število belih krvničk in krvnih ploščic.
The level of calcium, phosphate, magnesium and potassium in the blood may become too low without symptoms, but your doctor will monitor this and take necessary measures.
Koncentracije kalcija, fosfata, magnezija in kalija v krvi se lahko preveč znižajo, ne da bi se pokazali kakšni simptomi, vendar bo vaš zdravnik to spremljal in poskrbel za potrebne ukrepe.
HOW TO STORE ZOMETA
SHRANJEVANJE ZDRAVILA ZOMETA
Your doctor, nurse or pharmacist knows how to store Zometa properly.
Vaš zdravnik, medicinska sestra ali farmacevt vedo, kako je treba zdravilo Zometa pravilno shranjevati.
What Zometa contains − The active substance of Zometa is zoledronic acid. − The other ingredients are: mannitol, sodium citrate.
- Pomožni snovi sta manitol, natrijev citrat.
What Zometa looks like and contents of the pack Zometa is supplied as a powder in a vial.
Izgled zdravila in vsebina pakiranja Zdravilo je v obliki praška v viali.
Zometa is supplied as packs containing 1, 4 or 10 vials and 1, 4 or 10 ampoules, respectively.
Zometa je na voljo v ovojnini, v katerih je po 1 viala, 4 viale ali 10 vial in po 1 ampula, 4 ampule ali 10 ampul.
Manufacturer Novartis Pharma GmbH Roonstrasse 25 D-90429 Nuremberg Germany
Izdelovalec Novartis Pharma GmbH Roonstrasse 25 D- 90429 Nürnberg Nemčija
For further information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
54 INFORMATION FOR THE HEALTHCARE PROFESSIONAL
54 INFORMACIJE ZA ZDRAVSTVENE DELAVCE
− To prepare an infusion solution containing 4 mg Zometa, add 5 ml of water for injections from the ampoule supplied in the pack to the vial containing the Zometa powder under aseptic conditions.
- Infuzijsko raztopino, ki vsebuje 4 mg Zomete, pripravite tako, da aseptično dodate 5 ml vode za
Shake the vial gently to dissolve the powder.
injekcije iz ampule, ki je priložena v škatli, viali, ki vsebuje prašek Zometa.
− Further dilute the Zometa reconstituted solution (5 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution.
- Rekonstituirano raztopino Zomete (5 ml) dodatno razredčite s 100 ml infuzijske raztopine, ki ne
If a lower dose of Zometa is required, first withdraw the appropriate volume of the reconstituted solution (4 mg/ 5 ml) as indicated below and then dilute it further with 100 ml of infusion solution.
Če je potreben manjši odmerek Zomete, najprej odvzemite ustrezni volumen rekonstituirane raztopine (4 mg/ 5 ml), kot je navedeno spodaj, in ga nato dodatno razredčite s 100 ml infuzijske raztopine.
To avoid potential incompatibilities, the infusion solution used for dilution must be either 0.9% w/ v sodium chloride or 5% w/ v glucose solution.
Da ne bi prišlo do možnih inkompatibilnosti, mora biti infuzijska raztopina, ki se uporablja za razredčenje, bodisi 0, 9 -% m/ v raztopina natrijevega klorida bodisi 5 -% m/ v raztopina glukoze.
Do not mix Zometa reconstituted solution with calcium-containing or other divalent cation-containing solutions such as lactated Ringer’ s solution.
Ne mešajte rekonstituirane raztopine zdravila Zometa z raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata.
Instructions for preparing reduced doses of Zometa:
Navodila za pripravo zmanjšanih odmerkov Zomete:
Withdraw the appropriate volume of the reconstituted solution (4 mg/ 5 ml), as follows:
Odvzemite ustrezni volumen rekonstituirane raztopine (4 mg/ 5 ml), kot sledi:
4.4 ml for 3.5 mg dose 4.1 ml for 3.3 mg dose 3.8 ml for 3.0 mg dose
4, 4 ml za odmerek 3, 5 mg 4, 1 ml za odmerek 3, 3 mg 3, 8 ml za odmerek 3, 0 mg
− The Zometa infusion solution should preferably be used immediately.
Če je ne uporabite takoj, je
If the solution is not used immediately, storage prior to use is the responsibility of the care provider and should be in a refrigerator at 2°C – 8°C.
hranjenje pred uporabo odgovornost zdravstvenega delavca, raztopino pa je treba hraniti v hladilniku pri temperaturi 2 °C – 8 °C.
Allow the refrigerated solution to reach room temperature before administration.
Pred uporabo pustite, naj se ohlajena raztopina segreje na sobno temperaturo.
− The total time between reconstitution, dilution, storage in the refrigerator and end of administration must not exceed 24 hours.
dajanja zdravila ne sme preseči 24 ur.
− The solution containing Zometa is given as a single 15-minute intravenous infusion.
- Raztopino, ki vsebuje Zometo, dajemo v obliki ene same 15- minutne intravenske infuzije.
The hydration status of patients must be assessed prior to and following administration of Zometa to assure that they are adequately hydrated.
Status hidracije bolnikov mora zdravnik oceniti pred in po dajanju Zomete, da se prepriča, da so ustrezno hidrirani.
− Studies with glass bottles, several types of infusion bags and infusion lines made from polyvinylchloride, polyethylene and polypropylene (prefilled with 0.9% w/ v sodium chloride solution or 5% w/ v glucose solution) showed no incompatibility with Zometa.
sistemov, izdelanih iz polivinilklorida, polietilena in polipropilena (tovarniško napolnjenih z 0, 9 -% m/ v raztopino natrijevega klorida ali 5 -% m/ v raztopino glukoze), niso pokazale nezdružljivosti z Zometo.
− Since no data are available on the compatibility of Zometa with other intravenously administered substances, Zometa must not be mixed with other medications/ substances and should always be given through a separate infusion line.
podatkov, Zomete ne smete mešati z drugimi zdravili ali snovmi in jo morate vedno dajati po ločenem infuzijskem sistemu.
How to store Zometa
Če raztopine ne uporabite takoj,
− Keep Zometa out of the reach and sight of children. − Do not use Zometa after the expiry date stated on the pack. − The Zometa infusion solution should preferably be used immediately.
je za hranjenje pred uporabo odgovoren uporabnik, hraniti pa jo je treba v hladilniku pri temperaturi 2 °C – 8 °C.
If the solution is not used immediately, storage prior to use is the responsibility of the user and should be in a refrigerator at 2°C – 8°C. − The total time between reconstitution, dilution, storage in the refrigerator and end of administration must not exceed 24 hours.
- Celotni čas od rekonstitucije in razredčenja, shranjevanja v hladilniku do konca postopka
Read all of this leaflet carefully before you are given Zometa. − Ask your doctor, nurse or pharmacist if you have further questions. − Keep this leaflet.
- Če imate dodatna vprašanja, se posvetujte z zdravnikom, medicinsko sestro ali s farmacevtom.
You may need to read it again. − If any of the side effects gets serious, or if you notice side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.
- Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni
The Zometa concentrate requires further dilution before it is given as an infusion into a vein.
Koncentrat Zomete je treba dodatno razredčiti, preden jo dajo kot infuzijo v veno.
56 Ensure sufficient intake of liquids prior to infusions as directed by your doctor as this will help to prevent dehydration.
56 Poskrbite, da boste pred infuzijami zaužili dovolj tekočin, tako kot vam bo naročil zdravnik, ker bo to pomagalo preprečiti dehidracijo.
This is because you may develop serum electrolyte abnormalities (e. g. abnormal levels of calcium, phosphorus and magnesium) and/ or changes in kidney function, including severe kidney impairment.
57 Če ste prejeli večji odmerek zdravila Zometa, kot bi smeli Če ste prejeli odmerek, ki je večji od priporočenega, vas mora zdravnik natančno nadzorovati, zato ker lahko pride do nepravilnosti elektrolitov v serumu (do nepravilnih koncentracij kalcija, fosforja in magnezija) in/ ali do spremenjenega delovanja ledvic, vključno z ledvično odpovedjo.
Other common side effects are: − Gastrointestinal reactions such as nausea and vomiting, as well as loss of appetite. − Conjunctivitis, as reported with other bisphosphonates (the group of substances to which Zometa belongs). − Blood tests indicating changes in kidney function (higher levels of creatinine), including severe kidney impairment; such changes are also known to occur with other medicinal products of this kind.
- konjunktivitis (vnetje očesne veznice), o katerem poročajo pri drugih difosfonatih (skupina
Anaemia, a condition in which the number of red blood cells is decreased, has been reported; low counts of white blood cells and blood platelets have been observed.
Poročajo o anemiji, pri kateri je zmanjšano število rdečih krvničk; opazujejo zmanjšano število belih krvničk in krvnih ploščic.
What Zometa contains − The active substance of Zometa is zoledronic acid. − The other ingredients are: mannitol, sodium citrate, water for injections.
- Pomožne snovi so manitol, natrijev citrat, voda za injekcije.
What Zometa looks like and contents of the pack Zometa is supplied as a liquid concentrate in a vial.
Izgled zdravila in vsebina pakiranja Zdravilo je v obliki tekočega koncentrata v viali.
Zometa is supplied as packs containing 1, 4 or 10 vials.
Zometo izdajajo v ovojninah, ki vsebujejo po 1, 4 ali 10 vial.
60 INFORMATION FOR THE HEALTHCARE PROFESSIONAL
60 INFORMACIJE ZA ZDRAVSTVENE DELAVCE
How to prepare and administer Zometa
- Infuzijsko raztopino, ki vsebuje 4 mg Zomete, pripravite tako, da dodatno razredčite koncentrat
− To prepare an infusion solution containing 4 mg Zometa, further dilute the Zometa concentrate (5.0 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution.
Zomete (5, 0 ml) s 100 ml infuzijske raztopine, ki ne vsebuje kalcija ali drugih dvovalentnih kationov.
If a lower dose of Zometa is required, first withdraw the appropriate volume as indicated below and then dilute it further with 100 ml of infusion solution.
Če je potreben manjši odmerek Zomete, najprej odvzemite ustrezni volumen, kot je navedeno spodaj, in ga nato dodatno razredčite s 100 ml infuzijske raztopine.
To avoid potential incompatibilities, the infusion solution used for dilution must be either 0.9% w/ v sodium chloride or 5% w/ v glucose solution.
Da ne bi prišlo do možnih inkompatibilnost, mora biti infuzijska raztopina, ki se uporablja za razredčenje, bodisi 0, 9 -% m/ v raztopina natrijevega klorida bodisi 5 -% m/ v raztopina glukoze.
Do not mix Zometa concentrate with calcium-containing or other divalent cation- containing solutions such as lactated Ringer’ s solution.
Ne mešajte koncentrata zdravila Zometa z raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata.
Withdraw the appropriate volume of the liquid concentrate, as follows:
Odvzemite ustrezni volumen tekočega koncentrata, kot sledi:
− After preparation, Zometa infusion solution should preferably be used immediately.
Če je ne uporabite takoj,
If the solution is not used immediately, storage prior to use is the responsibility of the care provider and should be in a refrigerator at 2°C – 8°C.
je hranjenje pred uporabo odgovornost zdravstvenega delavca, raztopino pa je treba hraniti v hladilniku pri temperaturi 2 °C – 8 °C.
− The total time between dilution, storage in the refrigerator and end of administration must not exceed 24 hours.
- Celotni čas od razredčenja, shranjevanja v hladilniku do konca postopka dajanja zdravila ne sme
The hydration status of patients must be assessed prior to and following administration of Zometa to ensure that they are adequately hydrated.
Status hidracije bolnikov mora zdravnik oceniti pred in po dajanju Zomete, da se prepriča, da so ustrezno hidrirani.
− Since no data are available on the compatibility of Zometa with other intravenously administered substances, Zometa must not be mixed with other medications/ substances and should always be given through a separate infusion line.
podatkov, Zomete ne smete mešati z drugimi zdravili ali snovmi in jo moramo vedno dajati po ločenem infuzijskem sistemu.
− Keep Zometa out of the reach and sight of children. − Do not use Zometa after the expiry date stated on the pack. − The readily prepared Zometa infusion solution should preferably be used immediately.
- Zomete ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli.
If the solution is not used immediately, storage prior to use is the responsibility of the user and should be in a refrigerator at 2°C – 8°C. − The total time between dilution, storage in the refrigerator and end of administration must not exceed 24 hours.
ne uporabite takoj, je za hranjenje pred uporabo odgovoren uporabnik, hraniti pa jo je treba v hladilniku pri temperaturi 2 °C – 8 °C.
Zonegran is a medicine containing the active substance zonisamide.
Zonegran je zdravilo, ki vsebuje zdravilno učinkovino zonisamid.
It is available as capsules (25 mg: white; 50 mg: white and grey; 100 mg: white and red).
Na voljo je v obliki kapsul (25 mg: bele; 50 mg: bele in sive; 100 mg: bele in rdeče).
Zonegran is used as an add-on to existing epilepsy treatment in adult patients who have partial seizures (epileptic fits starting in one specific part of the brain).
Zdravilo Zonegran se uporablja kot dodatek že obstoječemu zdravljenju epilepsije pri odraslih bolnikih s parcialnimi napadi (epileptični napadi, ki se začnejo v krajevno določenem delu možganov).
It can be used in patients with and without secondary generalisation (where the seizure subsequently spreads to the whole brain).
Uporablja se lahko pri bolnikih z ali brez sekundarne generalizacije (pri kateri se napad razširi na cele možgane).
Zonegran must be added to the patient ’ s existing treatment.
Zdravilo Zonegran se mora dodati že obstoječemu zdravljenju bolnika.
The recommended starting dose is 25 mg twice a day with or without food.
Priporočeni začetni odmerek je 25 mg dvakrat na dan s hrano ali brez nje.
After one week the dose may be increased to 100 mg daily and then further increased in steps of 100 mg every week, depending on the patient’ s response.
Po enem tednu se lahko odmerek zdravila poveča na 100 mg dnevno, nato pa se ga lahko vsak teden poveča še za dodatnih 100 mg, kar je odvisno od odziva bolnika.
Zonegran can be given once or twice a day after an appropriate dose is reached.
Ko je primeren odmerek dosežen, se lahko zdravilo Zonegran daje enkrat ali dvakrat na dan.
Doses of 300 to 500 mg per day have been shown to be effective, but lower doses may be sufficient in some patients.
Dokazali so, da so učinkoviti odmerki od 300 do 500 mg na dan, vendar pri nekaterih bolnikih lahko zadostujejo že nižji odmerki.
The maximum daily dose is 500 mg.
Največji dnevni odmerek je 500 mg.
Dose increases may need to be made less frequently in patients with liver or kidney problems or those taking certain other medicines.
Pri bolnikih s težavami z jetri ali ledvicami ali tistih, ki jemljejo nekatera druga zdravila, bo morda potrebno manj pogosto povečevanje odmerka.
Zonegran should be used with caution in elderly patients and those with kidney problems.
Zdravilo Zonegran je treba uporabljati previdno pri starejših bolnikih in bolnikih s težavami z ledvicami.
It is not recommended for use in patients who have severe problems with their liver.
Uporaba zdravila ni priporočena pri bolnikih s hudimi težavami z jetri.
Before stopping Zonegran, the dose should be decreased gradually.
Pred prekinitvijo dajanja zdravila Zonegran je treba odmerek postopoma zmanjšati.
The active substance in Zonegran, zonisamide, is an anti-epileptic.
Zonisamid, zdravilna učinkovina zdravila Zonegran, je zdravilo proti epilepsiji.
Epileptic fits are caused by abnormal electrical activity in the brain.
Epileptične napade povzroča nenormalna električna aktivnost možganov.
Zonisamide works by blocking specific pores on the surface of nerve cells called sodium channels and calcium channels.
Učinkovina zonisamid blokira točno določene pore na površini živčnih celic, imenovane natrijevi kanalčki in kalcijevi kanalčki.
This reduces the chances of an epileptic fit.
Zonisamid z blokiranjem teh kanalčkov prepreči, da bi živčne celice uskladile svoje aktivnosti, in prepreči širjenje nenormalne električne aktivnosti po možganih.
This may help to stabilise electrical activity in the brain.
S tem se zmanjšajo možnosti pojava epileptičnega napada.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Zdravilo Zonegran deluje tudi 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. na živčnega prenašalca gama aminomasleno kislino (GABA, spojina, ki omogoča medsebojno sporazumevanje celic).
Zonegran has been studied as an add-on to existing treatment in one main study involving 351 patients with partial seizures.
Zdravilo Zonegran so preučevali kot dodatek obstoječemu zdravljenju v eni glavni študiji, ki je vključevala 351 bolnikov s parcialnimi napadi.
The study compared the effects of three doses of Zonegran with those of placebo (a dummy treatment).
V študiji so primerjali učinke treh odmerkov zdravila Zonegran z odmerki placeba (zdravila brez zdravilne učinkovine).
The doses of Zonegran were increased gradually over six weeks before an 18-week period on a stable dose.
V prvih šestih tednih so odmerke zdravila Zonegran najprej počasi povečevali, nato pa so 18 tednov dajali stabilne odmerke.
The main measure of effectiveness was the change in the frequency of partial seizures between the 12 weeks before treatment started and the 18-week period when a stable dose was used.
Glavno merilo učinkovitosti je bila sprememba v pogostosti parcialnih napadov, in sicer merjeno 12 tednov pred začetkom zdravljenja in nato v obdobju 18 tednov, ko so bolniki prejemali stabilen odmerek.
Zonegran was more effective than placebo at reducing the frequency of seizures.
Zdravilo Zonegran je bilo pri zmanjševanju pogostosti napadov učinkovitejše od placeba.
The patients taking 500 mg Zonegran per day had an average reduction in seizure frequency of 51%, compared with 16% in those taking placebo.
Pri bolnikih, ki so dnevno jemali 500 mg zdravila Zonegran, je pogostost napadov v povprečju padla za 51% v primerjavi s 16% pri tistih, ki so jemali placebo.
The most common side effects with Zonegran (seen in more than 1 patient in 10) are anorexia (loss of appetite), agitation, irritability, confusion, depression, ataxia (inability to co-ordinate muscle movements), dizziness, memory impairment, somnolence (sleepiness), diplopia (double vision) and decreased blood bicarbonate levels.
Najpogostejši neželeni učinki zdravila Zonegran (opaženi pri več kot 1 bolniku od 10) so anoreksija (izguba apetita), vznemirjenost, razdražljivost, zmedenost, depresija, ataksija (nezmožnost koordinacije gibov mišic), vrtoglavica, poslabšanje spomina, somnolenca (zaspanost), diplopija (dvojni vid) in znižane ravni bikarbonata v krvi.
Severe rashes have occurred in patients taking Zonegran, including cases of Stevens-Johnson syndrome (a severe, life-threatening type of allergic reaction).
Pri bolnikih, ki so jemali zdravilo Zonegran, so se pojavili hudi izpuščaji, ki so vključevali tudi primere Stevens- Johnsonovega sindroma (hud, življenjsko nevaren tip alergične reakcije).
For the full list of all side effects reported with Zonegran, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zonegran, glejte navodilo za uporabo.
Zonegran should not be used in people who may be hypersensitive (allergic) to zonisamide, to any of the other ingredients, or to sulphonamides (such as some antibiotics).
Zdravila Zonegran ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) zonisamid ali katero koli drugo sestavino zdravila ali sulfonamide (kot so nekateri antibiotiki).
The Committee for Medicinal Products for Human Use (CHMP) decided that Zonegran’ s benefits are greater than its risks as adjunctive therapy in the treatment of adult patients with partial onset seizures, with or without secondary generalisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Zonegran, uporabljenega kot dodatna terapija pri zdravljenju odraslih bolnikov s parcialnimi začetnimi napadi z ali brez sekundarne generalizacije, večje od z njim povezanih tveganj.
The Committee recommended that Zonegran be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Zonegran odobri dovoljenje za promet.
The European Commission granted a marketing authorisation valid throughout the European Union for Zonegran to Eisai Limited on 10 March 2005.
Evropska komisija je dovoljenje za promet z zdravilom Zonegran, veljavno po vsej Evropski uniji, odobrila družbi Eisai Limited dne 10. marca 2005.
The full EPAR for Zonegran can be found here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zonegran je na voljo tukaj.
EU Number EU/ 1/ 04/ 307/ 001 EU/ 1/ 04/ 307/ 002 EU/ 1/ 04/ 307/ 003 EU/ 1/ 04/ 307/ 004 EU/ 1/ 04/ 307/ 005 EU/ 1/ 04/ 307/ 006 EU/ 1/ 04/ 307/ 007 EU/ 1/ 04/ 307/ 008 EU/ 1/ 04/ 307/ 009 EU/ 1/ 04/ 307/ 010 EU/ 1/ 04/ 307/ 011 EU/ 1/ 04/ 307/ 012 EU/ 1/ 04/ 307/ 013
Številka postopka EU EU/ 1/ 04/ 307/ 001 EU/ 1/ 04/ 307/ 002 EU/ 1/ 04/ 307/ 003 EU/ 1/ 04/ 307/ 004 EU/ 1/ 04/ 307/ 005 EU/ 1/ 04/ 307/ 006 EU/ 1/ 04/ 307/ 007 EU/ 1/ 04/ 307/ 008 EU/ 1/ 04/ 307/ 009 EU/ 1/ 04/ 307/ 010 EU/ 1/ 04/ 307/ 011 EU/ 1/ 04/ 307/ 012 EU/ 1/ 04/ 307/ 013
Invented name Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran
Izmišljeno ime Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran Zonegran
Strength 25 mg 25 mg 50 mg 100 mg 25 mg 100 mg 100 mg 100 mg 50 mg 50 mg 100 mg 50 mg 25 mg
Jakost 25 mg 25 mg 50 mg 100 mg 25 mg 100 mg 100 mg 100 mg 50 mg 50 mg 100 mg 50 mg 25 mg